Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Katie Groves, S. Mouffak et al.|The Lancet Neurology|2021Cited by 260
A comprehensive framework for the interpretation of <i>TTN</i> missense variantsMaria Francesca Di Feo, Sushan Luo, Martin Rees et al.|medRxiv|2025Cited by 1
A comprehensive framework for the interpretation of TTN missense variantsMaria Francesca Di Feo, Sushan Luo, Martin Rees et al.|Figshare|2026Cited by 0
Additional file 2 of A comprehensive framework for the interpretation of TTN missense variantsMaria Francesca Di Feo, Sushan Luo, Martin Rees et al.|Figshare|2026Cited by 0
A comprehensive framework for the interpretation of TTN missense variantsMaria Francesca Di Feo, Sushan Luo, Martin Rees et al.|Figshare|2026Cited by 0